Furthermore, the inhibition of fascin activity by phosphorylation (Yamakita et al, 1996, Ono et al, 1997, Tilney et al, 1998; Adams et al, 1999, Cohan et al, 2001) or antisense oligonucleotide strategy (Al-Alwan et al, 2001) could represent potentially novel therapeutic options in the treatment of lung cancer. This evidence concerns the gene FSCN1 and lung cancer.